Originally Published as The Niche Podcast

Roche earns FDA approval for a combined flu/COVID diagnostic, I-Mab signs with Abbvie for $2 billion, PPD partners to treat lupus, and BioNTech/Pfizer add more COVID candidates while Moderna adds bad press.



Sponsors
www.thescopemethod.com

Story References
https://www.businesswire.com/news/home/20200903005517/en/PPD-Lupus-Therapeutics-Collaborate-Support-Lupus-Clinical
https://www.fiercebiotech.com/biotech/pfizer-biontech-quietly-usher-a-5th-covid-19-jab-into-clinic-analyst
https://www.npr.org/2020/09/04/908305074/bad-optics-or-something-more-moderna-executives-stock-sales-raise-concerns
https://www.roche.com/media/releases/med-cor-2020-09-04.htm
https://www.usnews.com/news/us/articles/2020-09-02/us-nih-awards-nine-companies-129-million-to-scale-up-covid-19-testing

Music by Luke Goodson
www.soundcloud.com/lukegoodson

 
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.